Indication: Miscellaneous Malignancies
A First-in-human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors
Sub-indication: Miscellaneous Malignancies
Drug Study
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Tizona Therapeutics, Inc.
